Trial Profile

A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 08 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

29 Apr 2026 According to a Neurocrine Biosciences Media Release, the data from the trial were published in The Journal of Clinical Psychiatry.
26 Mar 2026 According to a Neurocrine Biosciences Media Release, the baseline socio-demographic and clinical characteristics of the participants in this trial were broadly similar to the KINECT- 3 and KINECT-4 studies.
22 Sep 2025 According to a Neurocrine Biosciences Media Release, data from this trial were presented at the 38th annual Psych Congress in San Diego.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com